LSV Asset Management Has $508.91 Million Position in Gilead Sciences, Inc. $GILD
LSV Asset Management has significantly reduced its stake in Gilead Sciences, Inc. by 3.6% during the fourth quarter, now holding 4,146,280 shares valued at $508.91 million. Despite this reduction, Gilead Sciences remains the 11th largest position in LSV Asset Management's portfolio. Other institutional investors like Brighton Jones LLC, Bison Wealth LLC, and Sivia Capital Partners LLC have adjusted their positions in the biopharmaceutical company.
Global Retirement Partners LLC Grows Position in Gilead Sciences, Inc. $GILD
Global Retirement Partners LLC significantly increased its stake in Gilead Sciences, Inc. during the fourth quarter, acquiring an additional 14,414 shares and owning 32,281 shares valued at $3.96 million. This increased holding follows Gilead's strong quarterly financial results, featuring earnings of $2.03 per share on $6.96 billion in revenue, and positive developments like FDA approval for Hepcludex and a steady quarterly dividend. Other institutional investors also adjusted their positions, and insider sales collectively amounted to over $8.5 million in the last 90 days.
Assessing ImmunityBio (IBRX) Valuation After FDA Acceptance Of Anktiva sBLA For Papillary NMIBC
ImmunityBio (IBRX) is under valuation scrutiny following the FDA's acceptance of Anktiva's sBLA for BCG unresponsive papillary non-muscle invasive bladder cancer. Despite recent positive developments and strong long-term stock performance, the share price has seen a short-term decline. Analysts suggest a significant undervaluation, with a fair value of $13.50 against a current trading price of $7.22, highlighting the potential for future growth tied to global expansion and revenue increases, though risks remain if Anktiva's application remains narrow.
Gilead Sciences Inc. (NASDAQ: GILD) Holds Steady as HIV and Oncology Portfolio Drives Income
Gilead Sciences Inc. (NASDAQ: GILD) is demonstrating stability due to its strong HIV and growing oncology portfolios. The company's consistent cash generation, attractive dividend yield, and share repurchases make it a reliable income-oriented investment, especially during volatile market conditions. Analysts generally view GILD as a hold or buy, focusing on the growth of its oncology drug Trodelvy and the sustained performance of its HIV franchise.
Gilead Sciences Inc Stock (GILD) Closed Up by 3.04% on May 22: Drivers Behind the Movement
Gilead Sciences Inc. (GILD) stock closed up by 3.04% on May 22, outperforming its sector, driven primarily by significant advancements in its product pipeline and regulatory milestones. Key drivers include the FDA approval of Hepcludex for chronic hepatitis delta virus infection and the European Medicines Agency's positive recommendation for Trodelvy in advanced breast cancer. Despite some reports of insider selling and a lowered Q4 2026 EPS estimate, these positive developments provided a strong catalyst for the stock's upward movement.
Assembly Biosciences (NASDAQ: ASMB) launches stock and pre-funded warrant offering
Assembly Biosciences (NASDAQ: ASMB) is launching an offering of common stock and/or pre-funded warrants. The pre-funded warrants are exercisable at $0.001 per share, and Gilead Sciences, Inc. has shown a non-binding interest in purchasing a pro-rata number of shares. The proceeds from this offering are intended to fund clinical development of pipeline candidates and for general corporate purposes.
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
Gilead Sciences has received accelerated FDA approval for Hepcludex® (bulevirtide-gmod) as the first and only approved treatment for adults with chronic hepatitis delta virus (HDV) infection in the United States. Chronic HDV is the most severe form of viral hepatitis, leading to rapid liver disease progression, and the approval addresses a significant unmet medical need. The approval is based on data from the Phase 3 MYR301 study showing significant reductions in HDV RNA and normalization of ALT, with continued approval contingent on confirmatory trials.
US FDA approves Gilead's drug for deadly liver infection
The U.S. FDA has approved Gilead Sciences' drug Hepcludex for treating chronic hepatitis delta virus (HDV), a rare and deadly liver infection. This approval addresses a critical unmet medical need, as there were previously no FDA-approved treatments for HDV, which can lead to severe liver damage and death. The drug is significant for patients already infected with hepatitis B, who are susceptible to HDV.
US FDA approves Gilead's drug for deadly liver infection
The U.S. Food and Drug Administration has approved Gilead Sciences' drug, Hepcludex, for the treatment of chronic hepatitis delta virus (HDV). This rare and deadly liver infection previously had no approved treatment options, leading to conditions like scarring, cancer, organ failure, and death. The approval addresses a critical gap in care for affected patients.
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
Gilead Sciences has received accelerated FDA approval for Hepcludex (bulevirtide-gmod), making it the first and only approved treatment for chronic hepatitis delta virus (HDV) in the United States. This approval addresses a significant unmet medical need for HDV, considered the most severe form of viral hepatitis, based on data showing reductions in HDV RNA and normalization of alanine aminotransferase (ALT) in the Phase 3 MYR301 study. Continued approval for this indication will be contingent upon verification of clinical benefit in a confirmatory trial.
Gilead Sciences stock rises after FDA approves HDV treatment
Gilead Sciences Inc. (NASDAQ:GILD) shares rose 2.5% after the FDA approved Hepcludex (bulevirtide-gmod) for treating chronic hepatitis delta virus (HDV) infection in adults. This marks the first FDA-approved treatment for HDV, a serious condition that can lead to severe liver disease. Clinical trials demonstrated Hepcludex's efficacy, with a significant combined response and undetectable HDV RNA rates.
Gilead Sciences Inc. stock outperforms competitors on strong trading day
Gilead Sciences Inc. (GILD) saw its stock advance 2.96% to $134.36 on Friday, outperforming the broader market as the S&P 500 Index rose 0.37% and the Dow Jones Industrial Average rose 0.58%. Despite the strong trading day, the company's stock closed 14.58% below its 52-week high of $157.29, which was reached on February 11th.
AbbVie, Merck, Astra among winners of EU drug recommendations this week
The EU drug regulator's expert panel has recommended eight new medicines for approval this week, benefiting companies like Merck, AstraZeneca, and AbbVie. Merck's Keytruda, AstraZeneca's Enhertu, and AbbVie's Maviret received positive opinions for new indications, suggesting expanded market access and potential revenue growth. Pending final decisions from the European Commission could significantly impact the future revenue streams for these drugmakers by unlocking new sales volumes for larger or new patient groups.
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $180
Jefferies has reiterated its Buy rating for Gilead Sciences (GILD.US) and maintained a price target of $180. The content of the article is not available beyond this headline.
Crescent Biopharma (CBIO) FDA Approvals, PDUFA Dates & Drug Alerts 2026
Crescent Biopharma (CBIO) has not yet received any FDA approvals for its therapy CR-001, which is being investigated for the treatment of advanced solid tumors. The company recently announced a poster presentation for its ASCEND study of CR-001 at the 2026 ASCO Annual Meeting and previously reported dosing the first patient in its global Phase 1/2 clinical trial for the drug. Crescent Biopharma anticipates multiple data readouts for CR-001 starting in Q1 2027.
Gilead inks $140M API supply deal, tightening ties to Korean manufacturer
Gilead Sciences has signed a $139.8 million deal to source active pharmaceutical ingredients (APIs) from South Korea's Yuhan, expanding on their existing long-term relationship. This agreement, which started May 19 and runs until the end of next year, is the largest in a series of deals between the two companies. The move also aligns with a broader trend of U.S. companies diversifying API production away from China.
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
Gilead Sciences has received a positive opinion from the CHMP for Trodelvy (sacituzumab govitecan-hziy) as a monotherapy for first-line metastatic triple-negative breast cancer (TNBC) in patients ineligible for PD-(L)1 inhibitor therapy. This recommendation is based on the ASCENT-03 study, which showed significant progression-free survival benefits. The European Commission's decision is expected later in 2026, offering a crucial new treatment option for this aggressive form of breast cancer.
Keudell Morrison Wealth Management Purchases Shares of 16,022 Gilead Sciences, Inc. $GILD
Keudell Morrison Wealth Management has acquired a new stake of 16,022 shares in Gilead Sciences, valued at approximately $1.97 million during the fourth quarter. This acquisition highlights a trend of increased institutional investment, with various firms adjusting their positions in the biopharmaceutical company despite recent insider selling by executives. Gilead Sciences has shown strong financial performance, beating earnings estimates and declaring a quarterly dividend, while also making strategic acquisitions to strengthen its oncology pipeline.
Biotech Assembly Bio prices $100M sale to fund viral, liver drug work
Assembly Biosciences has priced a $100 million public offering of common stock and pre-funded warrants to fund clinical development of its pipeline candidates. The offering includes participation from new and existing healthcare-focused investors, notably Gilead Sciences, and is expected to close around May 26, 2026. This capital raise aims to advance Assembly Bio's work on therapeutics for serious viral and liver diseases, despite potential share dilution for current holders.
Gilead Sciences completes Tubulis acquisition for $5bn
Gilead Sciences has finalized its acquisition of Tubulis, a German biotechnology company specializing in advanced antibody-drug conjugates (ADCs), for up to $5 billion. The deal includes an upfront payment of $3.15 billion and up to $1.85 billion in milestone payments, enhancing Gilead's oncology portfolio with Tubulis's ADC technologies and pipeline assets. Tubulis's team will form Gilead's ADC Innovation Center in Munich, focusing on the development of novel ADCs for cancer treatment.
PNC Financial Services Group Inc. Has $58.19 Million Stake in Gilead Sciences, Inc. $GILD
PNC Financial Services Group Inc. increased its stake in Gilead Sciences, Inc. by 12.6% during the fourth quarter, bringing its total holdings to 474,105 shares valued at $58.19 million. Several other institutional investors also adjusted their positions in Gilead Sciences, while company insiders made significant stock sales. Wall Street analysts currently rate Gilead Sciences with a "Moderate Buy" and an average target price of $156.93.
Northwestern Mutual Wealth Management Co. Buys 13,252 Shares of Gilead Sciences, Inc. $GILD
Northwestern Mutual Wealth Management Co. increased its stake in Gilead Sciences, Inc. by 14.9%, purchasing an additional 13,252 shares, bringing their total holdings to 102,074 shares valued at approximately $12.5 million. This comes as Gilead Sciences reported better-than-expected quarterly earnings and revenue, and announced a quarterly dividend. Analysts maintain a "Moderate Buy" consensus rating for the stock with an average target price of $156.93.
TG Therapeutics Raises 2026 Outlook As Briumvi Drives Concentrated Growth
TG Therapeutics has raised its revenue guidance for 2026, primarily due to the strong performance of its multiple sclerosis drug, Briumvi. The company is actively pursuing new autoimmune indications for Briumvi, indicating a strategic focus on expanding its core product's market reach. While this approach concentrates both opportunity and risk, investors are showing confidence, with the stock up 29% in the past three months.
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
Gilead Sciences and its company Kite will present over 25 abstracts at the 2026 ASCO Annual Meeting and EHA Congress, showcasing momentum in antibody-drug conjugates (ADCs) and CAR T-cell therapy. Key presentations include new data for Trodelvy in first-line metastatic triple-negative breast cancer and anitocabtagene autoleucel (anito-cel) for relapsed or refractory multiple myeloma, along with updated Phase 1 results for Kite’s KITE-753 in B-cell lymphoma. These data highlight the increasing diversity and robust pipeline of Gilead's oncology portfolio, reinforcing its leadership in cancer therapeutics.
Return on assets % of Gilead Sciences, Inc. – BVL:GILDUS
The article displays the title "Return on assets % of Gilead Sciences, Inc. – BVL:GILDUS" and indicates that the market for GILDUS on the Lima Stock Exchange is closed with no trades. It is a page from TradingView providing financial data and an overview of Gilead Sciences, Inc.
Total debt of Gilead Sciences, Inc. – BVL:GILDUS
This article provides financial information specifically focusing on the total debt of Gilead Sciences, Inc. (GILDUS) listed on the Lima Stock Exchange. It indicates that the market for GILDUS was closed with no trades. The primary content available is a section titled "Total debt of Gilead Sciences, Inc." with placeholders for period, value, and change data.
Leukemia drug revumenib data to headline 4 ASCO 2026 talks
Syndax Pharmaceuticals announced that four abstracts related to its leukemia drug, Revuforj (revumenib), have been accepted for presentation at the ASCO 2026 Annual Meeting. These include an oral presentation on post-transplant maintenance data for acute leukemia patients, as well as posters detailing revumenib's pharmacokinetics and the design of two Phase 3 trials for newly diagnosed NPM1m or KMT2Ar AML. The presentations will highlight favorable outcomes and important profiles of the drug, while also reiterating warnings about potential adverse reactions like differentiation syndrome and QTc prolongation.
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
Gilead Sciences and its company Kite are set to present over 25 abstracts, including six oral presentations, at the 2026 ASCO Annual Meeting and EHA Congress. The presentations will highlight their progress in antibody-drug conjugates (ADCs) and CAR T-cell therapy, with key data supporting potential commercial launches for Trodelvy in metastatic triple-negative breast cancer and anito-cel for relapsed or refractory multiple myeloma. These data underscore the broadening diversity of Gilead's oncology portfolio and pipeline, aiming for long-term leadership in cancer treatment.
ETFs Investing in Gilead Sciences, Inc. Stocks
This article lists various ETFs that hold stock in Gilead Sciences, Inc. (GILDUS). It provides a detailed table including the market value, weight, issuer, management style, focus, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV total return for each ETF. The ETFs range from broad market funds like Vanguard Total Stock Market ETF to sector-specific funds like iShares Biotechnology ETF, offering diverse investment approaches.
Gilead Sciences, Inc. completed the acquisition of Tubulis GmbH from a group of shareholders.
Gilead Sciences, Inc. has successfully acquired Tubulis GmbH from its shareholders for a total of $5 billion. The deal includes $3.15 billion in upfront cash and up to $1.85 billion in contingent milestone payments. Tubulis will now operate as a dedicated ADC research organization within Gilead, with its Munich site becoming a hub for ADC innovation.
Gilead Sciences, Inc. Revenue Breakdown – BVL:GILDUS
Gilead Sciences, Inc. generated 99.08 billion PEN last year, with its Human Immunodeficiency Virus segment being the top performer, contributing 69.84 billion PEN. The United States was the primary regional contributor, accounting for 70.25 billion PEN of the total revenue.
Pharma M&A Roundup: Gilead Sciences Expands Collaboration with World Health Organization, Johnson & Johnson Enters Collaboration with Department of Health - Abu Dhabi
Gilead Sciences has expanded its collaboration with the World Health Organization, committing over 400,000 vials of AmBisome and $9.2 million by 2030 to combat visceral leishmaniasis, particularly in East Africa. Concurrently, Johnson & Johnson has partnered with the Department of Health – Abu Dhabi to establish a "surgical intelligence network," using AI and a centralized data platform to enhance surgical innovation and training across multiple healthcare providers in Abu Dhabi. Both initiatives highlight the growing trend of cross-sector collaborations to address global health challenges and advance medical technology.
Gilead pledges 400K AmBiosome doses to fight visceral leishmaniasis in expanded WHO collab
Gilead Sciences and the World Health Organization (WHO) have expanded their collaboration to eliminate visceral leishmaniasis (VL), a deadly parasitic disease. Gilead will donate over 400,000 vials of its AmBisome injection and provide an additional $9.2 million in financial support through 2030, focusing on East African countries where the global VL burden is highest. This expanded pact aims to accelerate progress toward eliminating the disease, building on a successful partnership that has already significantly reduced cases in Southwest Asia.
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
Gilead Sciences has successfully acquired Tubulis GmbH, a German biotechnology company specializing in next-generation antibody-drug conjugates (ADCs). This acquisition, valued at $3.15 billion upfront with potential milestones up to $1.85 billion, strengthens Gilead's oncology leadership by adding promising ADC assets like TUB-040 for platinum-resistant ovarian cancer. Tubulis will become "The Tubulis ADC Innovation Center" in Munich, continuing to develop advanced ADC technologies.
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
Gilead Sciences has successfully completed its acquisition of Tubulis GmbH, a clinical-stage biotechnology company specializing in next-generation antibody-drug conjugates (ADCs). The acquisition, valued at $3.15 billion upfront with up to $1.85 billion in milestone payments, strengthens Gilead's oncology portfolio with Tubulis's innovative ADC platform and lead assets like TUB-040 for platinum-resistant ovarian cancer. The Tubulis team will form the new Tubulis ADC Innovation Center in Munich, focusing on advancing ADC technology.
Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now
Moderna's stock has surged significantly year-to-date, but the article argues that its fundamentals remain weak with projected revenue collapse and cash burn. In contrast, Gilead Sciences is presented as a superior long-term investment due to its strong free cash flow generation, growing HIV franchise with extended patent protection, and consistent shareholder returns through dividends and buybacks. The author concludes that Gilead offers more stable, retirement-portfolio-quality returns compared to Moderna's headline-driven bounce.
Gilead Renews WHO Partnership to Fight Deadly Kala-Azar
Gilead Sciences Inc. has renewed its five-year collaboration with the World Health Organization (WHO) to combat visceral leishmaniasis (VL), also known as kala-azar. The renewed agreement includes funding, strategic support, and over 400,000 vials of AmBisome donations, with a stronger focus on high-burden countries in East Africa. This partnership aims to expand access to diagnosis and treatment, building on past successes that have reduced new VL cases by over 95% in Southeast Asia.
Gilead Puts $3.15B Into Next-Gen Cancer Drugs With Tubulis Buy
Gilead Sciences has completed its acquisition of Tubulis GmbH for $3.15 billion upfront and up to $1.85 billion in contingent milestone payments. This acquisition strengthens Gilead's oncology portfolio by adding next-generation antibody-drug conjugates (ADCs) and a platform designed for targeted cancer treatment. Tubulis' lead asset, TUB-040, an ADC for ovarian cancer, and TUB-030 for solid tumors, will complement Gilead's existing cancer therapies, with the Tubulis team forming an ADC Innovation Center in Munich.
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
Gilead Sciences and the World Health Organization (WHO) have announced an expanded five-year collaboration to eliminate visceral leishmaniasis (VL), also known as kala-azar. Gilead will donate over 400,000 vials of AmBisome® and provide $9.2 million in financial support through 2030, focusing on high-burden countries in East Africa. This partnership aims to improve access to diagnostics and treatment, building on prior success that saw a more than 95% reduction in new VL cases in Southeast Asia.
Leonteq Securities AG Takes Position in Gilead Sciences, Inc. $GILD
Leonteq Securities AG has initiated a new position in Gilead Sciences, Inc. (NASDAQ:GILD) by purchasing over 16,000 shares valued at approximately $1.98 million. This move comes as institutional investors and hedge funds significantly increase their holdings, collectively owning 83.67% of the company's stock. Gilead Sciences recently reported strong fourth-quarter earnings, beating analyst estimates with an EPS of $2.03 and revenues up 4.4% year-over-year, alongside maintaining a quarterly dividend of $0.82 per share.
Gilead Sciences extends WHO partnership to fight visceral leishmaniasis
Gilead Sciences has renewed its five-year collaboration with the World Health Organization to combat visceral leishmaniasis, a deadly parasitic disease. The company will donate over 400,000 vials of AmBisome and provide $9.2 million in financial support through 2030, focusing on high-burden countries in East Africa and other endemic regions. This expanded partnership aims to improve diagnostic services and treatment access, building on previous successes in reducing cases in Southeast Asia.
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
Gilead Sciences and the World Health Organization (WHO) have announced a renewed five-year collaboration to eliminate visceral leishmaniasis (VL), a deadly parasitic disease. Gilead will donate over 400,000 vials of AmBisome® and provide $9.2 million in financial support through 2030, focusing on high-burden countries in East Africa. This expanded agreement aims to improve access to diagnosis and treatment, building on previous success that reduced new VL cases by over 95% in Southeast Asia.
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
Gilead Sciences and the World Health Organization (WHO) have expanded their collaboration with a renewed five-year agreement to eliminate visceral leishmaniasis (VL), also known as kala-azar, a deadly parasitic disease. Gilead will donate over 400,000 vials of AmBisome® and provide $9.2 million in financial support through 2030, focusing on high-burden countries in East Africa. This partnership aims to improve access to diagnosis and treatment, building on previous success that saw a 95% reduction in new VL cases in Southeast Asia.
400,000 drug vials to fight a fatal parasite in 74% of VL hotspots
Gilead Sciences and the World Health Organization (WHO) have renewed their collaboration for another five years to accelerate the elimination of visceral leishmaniasis (VL), also known as kala-azar. Gilead will donate over 400,000 vials of AmBisome® (amphotericin B) liposome and $9.2 million in financial support through 2030 to countries representing 74% of the global VL burden, with a new focus on East Africa. This expanded agreement aims to improve access to diagnosis and treatment for the fatal parasitic disease, building on previous success in Southeast Asia where new cases were reduced by over 95%.
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
Gilead Sciences and the World Health Organization (WHO) have renewed their five-year collaboration to eradicate visceral leishmaniasis (VL), also known as kala-azar, a deadly parasitic disease. Gilead will contribute over 400,000 vials of AmBisome® and $9.2 million in financial support by 2030, focusing on high-burden countries in East Africa. This expanded partnership aims to enhance access to diagnostics and treatment, building on past success in reducing VL cases by over 95% in Southeast Asia.
Gilead Sciences Raised to Buy From Hold by Maxim Group
Maxim Group has upgraded its rating for Gilead Sciences (GILD) stock from Hold to Buy. The financial firm also set a price target of $100 for the biopharmaceutical company.
Gilead Sciences (GILD) prices multiple senior note series due 2028–2034
Gilead Sciences, Inc. (GILD) has issued four series of senior notes totaling $3 billion, with maturities ranging from 2028 to 2034 and interest rates between 4.250% and 4.900%. The notes were sold in a public offering using an existing Form S-3 shelf registration statement. The company intends to use the net proceeds for general corporate purposes, including potential acquisitions and strategic transactions, while the indenture includes standard protections for bondholders.
Inside Incyte’s $120 Million AI For Drug Development Deal
Incyte has signed a $120 million deal with Genesis Molecular AI for drug development, involving $80 million upfront and a $40 million equity investment, with potential for over $1 billion in milestone payments and royalties. This partnership integrates Incyte's proprietary data with Genesis's AI model to accelerate drug discovery across various therapeutic areas. Meanwhile, Apnimed has filed for regulatory approval for a sleep apnea drug, and Isomorphic Labs continues to raise significant capital for its AI-driven drug development efforts, focusing on an internal pipeline.
Gilead Sciences (NASDAQ:GILD) Upgraded to Buy at Maxim Group
Maxim Group has upgraded Gilead Sciences (NASDAQ:GILD) from a "hold" to a "buy" rating, setting a $165 price target, which implies a 26% upside. This upgrade follows Gilead's recent quarterly results, which exceeded expectations with EPS of $2.03 and revenues of $6.96 billion, marking a 4.4% year-over-year increase. Despite recent insider selling by CEO Daniel Patrick O’Day and executive Johanna Mercier, analyst sentiment for GILD remains largely positive, with 25 Buy ratings against only four Hold ratings.
Maxim Upgrades Gilead Sciences to Buy From Hold, Price Target Is $165
Maxim has upgraded Gilead Sciences (GILD) from a "Hold" rating to a "Buy" rating, setting a new price target of $165. The article also briefly mentions Unity Software's Q4 earnings, where its revenue increased 35% year-over-year to $609 million, exceeding estimates, despite reporting a quarterly loss of 66 cents per share.
